Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 38.3% during the first quarter, HoldingsChannel reports. The institutional investor owned 1,339,702 shares of the company’s stock after selling 833,046 shares during the period. Assenagon Asset Management S.A.’s holdings in Teva Pharmaceutical Industries were worth $40,352,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Menora Mivtachim Holdings LTD. boosted its stake in Teva Pharmaceutical Industries by 1.1% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock worth $786,190,000 after purchasing an additional 427,000 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of Teva Pharmaceutical Industries by 2.0% in the third quarter. Victory Capital Management Inc. now owns 2,360,762 shares of the company’s stock valued at $47,687,000 after buying an additional 45,395 shares during the last quarter. Legal & General Group Plc raised its position in shares of Teva Pharmaceutical Industries by 6.8% in the fourth quarter. Legal & General Group Plc now owns 3,608,387 shares of the company’s stock valued at $112,618,000 after buying an additional 228,189 shares during the last quarter. WealthTrust Asset Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter worth about $856,000. Finally, HighTower Advisors LLC boosted its position in Teva Pharmaceutical Industries by 167.9% during the third quarter. HighTower Advisors LLC now owns 172,802 shares of the company’s stock worth $3,491,000 after acquiring an additional 108,311 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $33.68 on Friday. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The firm has a market capitalization of $38.73 billion, a price-to-earnings ratio of 25.32, a PEG ratio of 4.18 and a beta of 0.84. The company’s 50-day moving average is $33.70 and its two-hundred day moving average is $32.38. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The business had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. Analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on TEVA shares. UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Bank of America raised their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Barclays increased their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Finally, Truist Financial lifted their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average target price of $41.78.

Insider Buying and Selling

In other news, insider Mark Sabag sold 144,180 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the transaction, the insider owned 80,760 shares of the company’s stock, valued at $2,825,792.40. This represents a 64.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Eliyahu Sharon Kalif sold 153,251 shares of the stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the transaction, the executive vice president owned 172,184 shares of the company’s stock, valued at approximately $6,131,472.24. This represents a 47.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 465,931 shares of company stock valued at $16,332,989 in the last ninety days. Company insiders own 0.54% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.